Search

Changes to Formulary as of 1st April 2019:

 

BNF Category Number

Product/indication

Detail of change

8.1.5

Lenvatinib

Added link to NICE TA551

 8.1.5

Liposomal cytarbine-daunorubicin

Added link to NICE TA552

8.1.5

Pembrolizumab

Added link to NICE TA553 & NICE TA557

8.1.5

Tisagenlecleucel

Added as RED drug and added link to NICE TA554

8.1.5

Regorafenib

Added link to NICE TA555

8.1.5

Nivolumab

Added link to NICE TA558

8.1.5

Axicabtagene ciloeucel

Added as RED drug and added link to NICE TA559

4.7.2

Dipipanone (Diconal®)

Added as NOT APPROVED drug

5.1.7

Linezolid (oral)

Clarified courses >14 days are RED drug

2.6.3

Ranolazine

Removed need for cardiology to all dose titration

5

 

Added link to NICE NG114 and NG117

3

 

Added link to NICE NG115

4

 

Added link to NICE NG118

7

 

Added link to NICE NG119

 

Valproate

Added link to MHAR DSU and changed RAG status to AMBER for use in females of child bearing potential

13.2

Emollients

Added link to MHRA DSU

5.3.3.2

Direct acting antivirals for chronic hep c

Added link to MHRA DSU

12.3.1

Hydrocortisone muco-adhesive buccal tablets

Added link to MHRA DSU

4.7.2

Tapentadol

Added link to MHRA DSU

11.3.3

Acyclovir eye ointment

Removed from formulary as discontinued and ganciclovir eye gel changed to GREEN

8.1.5

Ipilimumab

Added link to MHRA DSU